RSS   Newsletter   Contact   Advertise with us

Emergent BioSolutions signs agreement for large scale coronavirus vaccine substance manufacturing

Christian Fernsby ▼ | July 6, 2020
Emergent BioSolutions announced a five year manufacturing services agreement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson and Johnson, for large scale drug substance manufacturing for Johnson and Johnson’s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology.
Emergent BioSolutions
Substance   Emergent BioSolutions
Emergent will provide contract development and manufacturing (CDMO) services to produce drug substance at large scale over five years, valued at approximately $480 million for the first two years.

Topics: Emergent BioSolutions

Under the agreement, Emergent will begin providing large scale drug substance manufacturing for Johnson and Johnson’s adenovirus-based coronavirus vaccine in 2021, upon successful completion of the activities under the previously executed Technology Transfer Agreement.

For the subsequent years beginning 2023, Emergent will provide a flexible capacity deployment model to support additional drug substance batches annually.